Alexion, AstraZeneca’s Rare Disease group, has entered into a settlement agreement with Chugai Pharmaceutical, resolving all patent disputes between the two companies related to Ultomiris (ravulizumab).
In accordance with the settlement agreement, Alexion and Chugai have taken steps to withdraw patent infringement proceedings filed with US District Court for the District of Delaware and Tokyo District Court, states AstraZeneca.
“With this settlement, we will continue to advance our Ultomiris development programmes in new indications and focus on our mission to transform the lives of people affected by rare diseases,” says Marc Dunoyer, Chief Executive Officer, Alexion.
Under the terms of the agreement, Alexion will make a single payment of 775 million USD in the second quarter of 2022, for which a charge will be recognized through the non-core P&L in the first quarter of 2022. No further amounts are payable by either party.
Photo of Marc Dunoyer: AstraZeneca